GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » ROC (Joel Greenblatt) %

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) ROC (Joel Greenblatt) % : 0.00% (As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. RespireRx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for RespireRx Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

During the past 13 years, RespireRx Pharmaceuticals's highest ROC (Joel Greenblatt) % was -15235.29%. The lowest was -101682.35%. And the median was -59334.83%.

RSPI's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -329.055
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

RespireRx Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


RespireRx Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for RespireRx Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RespireRx Pharmaceuticals ROC (Joel Greenblatt) % Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RespireRx Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, RespireRx Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



RespireRx Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.134) - (5.89 + 0 + 3.447)
=-9.203

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.103) - (6.628 + 0 + 2.652)
=-9.177

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of RespireRx Pharmaceuticals for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.288/( ( (0 + max(-9.203, 0)) + (0 + max(-9.177, 0)) )/ 1 )
=-1.288/( ( 0 + 0 )/ 1 )
=-1.288/0
= %

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RespireRx Pharmaceuticals  (OTCPK:RSPI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


RespireRx Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
Executives
David Dickason officer: SVP of Pre-Clinical Prod. Dev. 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones director, officer: CEO and President 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J director, officer: President & CEO 5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr. officer: SVP - Research & Deleopment 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin officer: Controller 33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten director, officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc other: Member of a 10% owner group 354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp other: Member of 10% owner group
Jeff Eliot Margolis director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik other: Member of 10% owner group C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa director, officer: Chairman, CEO and President, other: Member of 10% owner group C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen other: Member of 10% owner group 12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Headlines

From GuruFocus